Please login to the form below

Not currently logged in
Email:
Password:

Rotarix

This page shows the latest Rotarix news and features for those working in and with pharma, biotech and healthcare.

Takeda starts trial of norovirus vaccine

Takeda starts trial of norovirus vaccine

If approved the drug is anticipated to surpass sales of GSK’s Rotarix vaccine. ... Market observers have suggested that - if approved - the vaccine could meet or even exceed sales of GSK's Rotarix vaccine for rotavirus-related diarrhoea, which was

Latest news

  • Pfizer's Prevenar 13 price cut slammed by MSF Pfizer's Prevenar 13 price cut slammed by MSF

    GSK committed to a 10-year price freeze for Synflorix - currently selling at $3.40 per dose - as well as other vaccines provided to GAVI including rotavirus vaccine Rotarix and the

  • Sanofi unit takes low-cost rotavirus vaccine into phase III Sanofi unit takes low-cost rotavirus vaccine into phase III

    The study - conducted by Sanofi affiliate Shantha Biotechnics - aims to show that the live-attenuated vaccine candidate is at least as good as currently-licensed vaccines such as GlaxoSmithKline's Rotarix ... III trials, promising to make it available at

  • Merck & Co and GSK offer discounted cervical vaccines to developing nations

    GSK has an existing relationship with GAVI, and has agreements in place to provide rotavirus vaccine Rotarix and pneumococcal polysaccharide conjugate vaccine Synflorix to the Alliance at reduced prices for use

  • GSK offers UNICEF rotavirus vaccine

    GSK has offered its rotavirus vaccine Rotarix to the GAVI Alliance at a reduced price following a UNICEF request. ... GSK has made a new offer to supply its rotavirus vaccine Rotarix to the GAVI Alliance at $2.50 per dose, in response to a UNICEF request.

  • Q2 net loss for GSK

    Sales in the US were impacted by individual factors and adverse prior year comparisons, such as an acceleration of generic competition to Valtrex (valacyclovir), the temporary suspension of Rotarix (rotavirus vaccine),

More from news
Approximately 1 fully matching, plus 22 partially matching documents found.

Latest appointments

  • Johan Heylen leaves GSK for Ablynx Johan Heylen leaves GSK for Ablynx

    In this role he headed the global commercial teams of GSK and was responsible for the development and implementation of the launch strategy for several drugs, including Rotarix, Priorix and Varilix.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...